CD40 and the Effect of Anti-CD40-Binding on Human Multiple Myeloma Clonogenicity

References

• Stone M. J. Monoclonal gammopathies: Clinical Aspects. Pathology of Immunoglobulins: Diagnostic and Clinical Aspects Protein Abnormalities, SE Ritzmann, New York, NY 1982; Vol 2: 161
   Google Scholar
• Klein B., Bataille R. Cytokine network in human multiple myeloma. Hematol. Oncol. Clin. N. America 1992; 6: 273
   PubMed Web of Science ®Google Scholar
• Moscinski L. C., Ballester O. F. Recent progress in multiple myeloma. Hematol. Oncol 1994; 12: 111
   PubMed Web of Science ®Google Scholar
• Mandelli F., Avisati G., Tribalto M. Biology and treatment of multiple myeloma. Current Opin. Oncol 1992; 4: 73
   PubMedGoogle Scholar
• Tong A. W., Hanson T., Zhang B., Stone M. J. Stimulation of human multiple myeloma clonogenic colonies by a monoclonal antibody to the B lineage antigen CD40 (Abstract). Blood 1992; 80, (Suppl I)
   Google Scholar
• Gordon J., Katira A., Holder M., MacDonald I., Pound J. Central role of CD40 and its ligand in B lymphcyte responses to T-dependent antigens. Cell Mol. Biol 1994; 40, (Suppl I)
   PubMed Web of Science ®Google Scholar
• Hollenbaugh D., Ochs H. D., Noelle R. J., Ledbetter J. A., Aruffo A. The role of CD40 and its ligand in the regulation of the immune response. Immunol. Rev 1994; 138: 23
   PubMed Web of Science ®Google Scholar
• Liu Y. J., Joshua D. E., Williams G. T., Smith C. A., Gordon J., MacLennan I. C. M. Mechanism of antigen-drive selection in germinal centres. Nature 1989; 342: 929
   PubMed Web of Science ®Google Scholar
• Splawski J. B., Fu S. M., Lipsky P. E. Immunoregulatory role of CD40 in human B cell differentiation. J. Immunol 1993; 150: 1276
   PubMed Web of Science ®Google Scholar
• Clark E. A., Shu G. Association between IL-6 and CD40 signaling. IL-6 induces phosphorylation of CD40 receptors. J. Immunol 1990; 145: 1400
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X. G., Lu Z. Y., Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863
   PubMed Web of Science ®Google Scholar
• Tong A. W., Zhang B. Q., Mues G., Solano M., Hanson T., Stone M. J. Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. Blood 1994; 84: 3026
   PubMed Web of Science ®Google Scholar
• Westendorf J. J., Ahmann G. A., Armitage R. J., Spriggs M. K., Lust J. A., Greipp P. R., Katzmann J. A., Jelinek D. F. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J. Immunol 1994; 152: 117
   PubMed Web of Science ®Google Scholar
• Bakkus M. H. C., Riet I. V., De Greef C., de Boer M., Thielemans K., Van Camp B. Expression of activation molecules (CD40, B7 and CD28) in human multiple myeloma. Proc IV Intl Workshop on Multiple Myeloma 127. Mayo Medical Center, Rochester 1993
   Google Scholar
• Pellat-Deceunynck C., Bataille R., Robillard N., Harousseau J. L., Rapp M. J., Juge-Morineau N., Wijdenes J., Amlot M. Expression of CD28 and CD40 in human myeloma cells: A comparative study with normal plasma cells. Blood 1994; 84: 2597
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Gajil-Peczalska K., Myers D. E., Jaszca W., Haissig S., Ledbetter J. A. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 1990; 76: 2449
   PubMed Web of Science ®Google Scholar
• Stamenkovich I., Clark E. A., Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 1989; 8: 1403
   PubMed Web of Science ®Google Scholar
• Carbone A., Glogini A., Gattei V., Aldinucci D., Degan M., De Paoli P., Zagonel V., Pinto A. Expression of functional CD40 antigen on Reed-Stemberg cells and Hodgkin's disease cell lines. Blood 1995; 85: 780
   PubMed Web of Science ®Google Scholar
• Smith G. A., Farrah T., Goodwin R. G. The TNF receptor superfamily of cellular and viral proteins: Activation, co-stimulation, and death. Cell 1994; 76: 959
   PubMed Web of Science ®Google Scholar
• Clement M. V., Stamenkovic I. Fas and tumor necrosis factor receptor-mediated cell death: Similarities and distinctions. J. Exp. Med 1994; 180: 557
   PubMed Web of Science ®Google Scholar
• Barrett T. B., Shu G., Clark E. A. CD40 signaling activates CD11a/CD18 (LFA-1)-mediated adhesion in B cells. J. Immunol 1991; 146: 1722
   PubMed Web of Science ®Google Scholar
• Rousett F., Garcia E., Defrance T., Peronne C., Vezzio N., Hsu D. H., Kastelein R., Moore K. W., Banchereau J. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. USA 1992; 89: 1890
   PubMed Web of Science ®Google Scholar
• Burdin N., Kooten C. V., Gailibert L., Abrams J. S., Wijdenes J., Banchereau J., Rousset F. Endogenous IL-6 and IL-10 contribute to the differentiation of CD-activated human B lymphocytes. J. Immunol 1995; 154: 2533
   PubMed Web of Science ®Google Scholar
• Durandy A., De St Basile G., Lisowska-Grospierre B., Gauchat J. F., Forveille M., Kroczek R. A., Bonnefoy J. Y., Fischer A. Undetectable CD40 ligand expression on T cells and low B cell responses to CD40 binding agonists in human newborns. J. Immunol 1995; 154: 1560
   PubMed Web of Science ®Google Scholar
• Inghirami G., Lederman S., Yellin M. J., Chadburn A., Chess L., Knowles D. M. Phenotypic and functional characterization of T-BAM (CD40 ligand)+ T-cell non-Hodgkin's lymphoma. Blood 1994; 84: 866
   PubMed Web of Science ®Google Scholar
• Cocks B. G., de Waal Malefyt M. R., Galizzi G. J., de Vries J. E., Aversa G. IL-13 induces proliferation and differentiation of human B cell activated by the CD40-ligand. Int. Immunol. J 1992; 5: 657
   Web of Science ®Google Scholar
• Lederman S., Yellin M., Cleary A., Pemis A., Inghirami G., Cohn L., Covey L., Lee J., Rothman P., Chess L. The T-BAM/CD40L molecule on helper T lymphocytes augments lymphokine-induced B cell immunoglobulin isotype switch recombination and rescues B cells from programmed cell death. J. Immunol 1994; 152: 2163
   PubMed Web of Science ®Google Scholar
• Foy T. M., Laman J. D., Ledbetter J. A., Aruffo A., Claasen E., Noelle R. J. Gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J. Exp. Med 1994; 180: 157
   PubMed Web of Science ®Google Scholar
• Yellin M. J., Sinning J., Covey L. R., Sherman W., Lee J. J., Glickman-Nir E., Sippel K. C., Rogers J., Cleary A. M., Parker M., Chess L., Lederman S. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J. Immunol 1994; 153: 666
   PubMed Web of Science ®Google Scholar
• Lederman S., Yellin M. J., Inghirami G., Lee J. J., Knowles D. M., Chess L. Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles: Roles of T-BAM (5c8 Ag) and CD40 in contract-dependent help. J. Immunol 1992; 149: 3817
   PubMed Web of Science ®Google Scholar
• Aruffo A. M., Farrington D., Hollenbaugh D., Li Z., Milatovich S., Nonoyama J., Bajorath L. S., Grosmarie S., Stenkamp M. Neubauer. The CD40 ligand gp39 is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993; 72: 29
   PubMed Web of Science ®Google Scholar
• Farrington M., Grosmaire L. S., Nonoyama S., Fischer S. H., Hollenbaugh D., Ledbetter J. A., Noelle R. J., Aruffo A., Ochs H. D. CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc. Natl. Acad. Sci. USA 1994; 91: 1099
   PubMed Web of Science ®Google Scholar
• Callard R. D., Smith S. H., Herbert J., Morgan G., Padayachee M., Lederman S., Chess L., Kroczek R. A., Fanslow W. C., Armitage R. J. CD40 ligand (CD40L) expression and B cell function in agammaglobulinemia with normal or elevated levels of IgM (HIM). J. Immunol 1994; 153: 3295
   PubMed Web of Science ®Google Scholar
• Durie F. H., Aruffo A., Ledbetter J., Crassi K. M., Green W. R., Fast L. D., Noelle R. J. Antibody to the ligand of CD40, gp 39, blocks the occurrence of the acute and chronic forms of graftvs-host disease. J. Clin. Invest 1994; 94: 1333
   PubMed Web of Science ®Google Scholar
• Durie F. H., Fava R. A., Noelle R. J. Collagen-induced arthritis as a model of rheumatoid arthritis. Clin. Immunol. Immunopath 1994; 73: 11
   PubMedGoogle Scholar
• Mohan C., Shi Y., Laman J. D., Datta S. K. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol 1995; 154: 1470
   PubMed Web of Science ®Google Scholar
• Jackson N., Ling N. R., Ball J., Bromidge E., Nathan P. D., Franklin I. M. An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd international workshop on human leucocyte differentiation antigens. Clin. Exp. Immunol 1988; 72: 351
   PubMed Web of Science ®Google Scholar
• Hamilton M. S., Ball J., Bromidge E., Franklin I. M. Specific antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion. Br. J. Haematol 1992; 78: 60
   Web of Science ®Google Scholar
• Urashima M., Chauhan D., Uchiyama H., Freeman G. J., Anderson K. C. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 1995; 85: 1903
   PubMed Web of Science ®Google Scholar
• Tong A. W. Unpublished observations. 1995
   Google Scholar
• Kawano M., Huang N., Harada H., Harada Y., Sakai A., Tanaka H., Iwato K., Kuramoto A. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 1993; 82: 564
   PubMed Web of Science ®Google Scholar
• Harada H., Kawano M. M., Huang N., Harada Y., Iawato K., Tanabe O., Tanaka H., Sakai A., Asaoku H., Kuramoto A. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993; 81: 2658
   PubMed Web of Science ®Google Scholar
• Karp J. E., Burke P. J., Saylor P. L., Humphrey R. L. Correlation of proliferative and clonogenic tumor cells in multiple myeloma. Cancer Res 1984; 44: 4197
   PubMed Web of Science ®Google Scholar
• Durie B. G. M., Salmon S. E., Moon T. E. Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 1980; 55: 364
   PubMed Web of Science ®Google Scholar
• Zhang X., Childs B., Siegel D., Nievsvizky R., Zelenetz A., Michaeli J. A novel clonogenic assay for the growth of human myeloma cells in vitro (abstract). Blood 1994; 84, (Suppl I)
   Web of Science ®Google Scholar
• Rhodes E. G., Olive C., Flynn M. P. A serum-free cultures method for myeloma progenitors in vitro: Proliferative and immunophenotypic characteristics. Exp. Hematol 1990; 18: 79
   PubMed Web of Science ®Google Scholar
• Kyle R. A. Prognostic factors in multiple myeloma. Hematol. Oncol 1988; 6: 125
   PubMed Web of Science ®Google Scholar
• Borinaga A. M., Millar B. C., Bell J. B., Joffe J. K., Millar J. L., Gooding R., Riches P., McElwain T. J. Interleukin-6 is a cofactor for the growth of myeloid cells from human bone marrow aspirates but does not affect the clonogencity of myeloma cells in vitro. Br. J. Haematol 1990; 76: 476
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C., Amlot M., Robillard N., Bataille R. Human myeloma cell growth arrest induced by CD40 stimulation (Abstract). Blood 1994; 84, (Suppl I)
   PubMed Web of Science ®Google Scholar
• Law C. L., Wormann B., LeBien T. W. Analysis of expression and function on normal and leukemic human B cell precursors. Leukemia 1990; 4: 732
   PubMed Web of Science ®Google Scholar
• Snapper C. M., Kehry M. R., Castle B. E., Mond J. J. Multivalent, but not divalent, antigen receptor cross linkers synergize with CD40 ligand for induction of Ig synthesis and class switching in normal murine B cells. J. Immunol 1995; 154: 1177
   PubMed Web of Science ®Google Scholar
• Fluckiger A. C., Rossi J. F., Bussel A., Byron P., Banchereau J., Defrance T. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 1992; 80: 3173
   PubMed Web of Science ®Google Scholar
• Funakoshi S., Longo D. L., Beckwith M., Conley D. K., Tsarfaty G., Tsarfaty I., Armitage R. J., Fanslow W. C., Spriggs M. K., Murphy W. J. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994; 83: 2787
   PubMed Web of Science ®Google Scholar
• Kaufman Y., Many A., Rechavi G., Mor O., Biniaminov M., Rosenthal E., Levanon M., Davidsohn J., Aizman I., Mark Z., Brok-Simoni F., Ramot B. Lymphoma with recurrent cycles of spontaneous remission and relapse–Possible role of apoptosis. New Engl. J. Med 1995; 332: 507
   PubMed Web of Science ®Google Scholar
• Brenning G. The in vitro effect of leucocyte alpha-interferon on human myeloma cells in a semisolid agar culture system. Scand. J. Haematol 1985; 35: 178
   PubMedGoogle Scholar
• Ludwig C. U., Durie B. G. M., Salmon S. E., Moon T. E. Tumor growth stimulation in vitro by interferons. Eur. J. Cancer Clin. Oncol 1983; 19: 1625
   PubMedGoogle Scholar
• Peest D., Deicher H., Coldewey R. Mephalan and prednisone vs vinscristinie, BCNU, Adriamycin, melphalan, and dexamethasone induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multi-center trial. The German myeloma treatment group. Oncologie 1990; 13: 458
   Google Scholar
• Kansas G. S., Tedder T. F. Transmembrane signals generated through MHC class II, CD19, CD20, CD39 and CD40 antigens induce LFA-I dependent and independent adhesion in human B cells through a tyrosine-dependent pathway. J. Immunol 1991; 147: 4094
   PubMed Web of Science ®Google Scholar
• Uckun F., Schieven G., Dibirdik I., Chandan-Langlie M., Tuel-Ahlgren I., Ledbetter J. A. Stimulation of protein tyrosine phosphorylation, phosphoinositide turnover, and multiple previously unidentified serine/threonine-specific protein kinases by the pan-B-cell receptor CD40/BP50 at discrete developmental stages of human B-cell ontogeny. J. Biol. Chem 1991; 266: 17478
   PubMed Web of Science ®Google Scholar
• Ren C., Geha R. CD40 engagement activates LYN kinase and phosphorylates PLC-γ2. J. Cell Biochem 1993; 169, (Suppl. 17B)
   Google Scholar
• Clapham D. E. Calcium signaling. Cell 1995; 80: 259
   PubMed Web of Science ®Google Scholar
• Berberich I., Shu G. L., Clark E. A. Cross-linking CD40 on B cells rapidly activates nuclear factor-kB. J. Immunol 1994; 153: 4357
   PubMed Web of Science ®Google Scholar
• Sha W. C., Liou H. C., Tumonanen E. I., Baltimore D. Targeted disruption of the p50 subunit of NF-kB leads to multifocal defects in immune responses. Cell 1995; 80: 321
   PubMed Web of Science ®Google Scholar
• Marshall C. J. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80: 179
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F., Bergui L., Gregoretti M. G., Gaidano G., Gaboli M., Schena M., Zallone A., Marchisio P. C. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991; 77: 2688
   PubMed Web of Science ®Google Scholar
• Mellstedt H., Holm G., Pettersson D., Peest D. Idiotype-bearing lymphoid cells in plasma cell neoplasia. Clin. Haematol 1982; 11: 65
   PubMedGoogle Scholar
• Jensen G. S., Mant M. J., Belch A. J., Berenson J. R., Reuther B. A., Pilarski L. M. Selective expression of CD45 isoforms defines CALLA + monoclonal B lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 1991; 78: 711
   PubMed Web of Science ®Google Scholar
• Bergsagel P. L., Belch A. R., Pilarski L. M. The blood B cells and bone marrow plasma cells in a patient with multiple myeloma include cells with the same N-ras mutation (Abstract). Blood 1994; 84, (Suppl I)
   Web of Science ®Google Scholar
• DeGrassi A., Hibert D. M., Rudikoff S., Anderson A. O., Potter M., Coon H. G. In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc. Natl. Acad. Sci. USA 1993; 90: 2060
   PubMed Web of Science ®Google Scholar
• Chabannon C., Mannoni P. Role of growth factors in the control of leukemic cell proliferation. Leukemia Lymphoma 1994; 13, (Suppl I)
   PubMed Web of Science ®Google Scholar
• Nagata K., Tanaka Y., Oda S., Yamashita U., Eto S. Interleukin 1 autocrine growth system in human multiple myeloma. Jpn. J. Clin. Oncol 1991; 21: 22
   PubMed Web of Science ®Google Scholar
• Herrman F., Andreeff M., Gruss H. J., Brach M. A., Lubbert M., Mertelsman R. Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. Blood 1991; 78: 2070
   PubMed Web of Science ®Google Scholar
• Ameglio F., Alvino S., Trento E., Marcucci M., Pimpinelli F., Tong A. W., Gandolf G. M., Greco C. Serum interleukin-10 levels in patients affected with multiple myeloma: Correlation with the monoclonal component and disease progression. Int. J. Oncol 1995; 6: 1189
   PubMed Web of Science ®Google Scholar
• Palumbo A., Battaglio S., Napoli P., Omede P., Fusaro A., Bruno B., Boccadoro M., Pileri A. Recombinant interferongamma inhibits the in viro proliferation of human myeloma cells. Br. J. Haematol 1994; 86: 726
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Schoester M., de Leeuw K. In vitro Igsynthesis and proliferative activity in multiple myeloma are stimulated by different growth factors. Br. J. Haematol 1991; 79: 589
   PubMed Web of Science ®Google Scholar
• Valle A., Zuber C. E., Defrance T., Djossou O., de Rie M., Banchereau J. Activation of human B lymphocytes through CD40 and interleukin 4. Eur. J. Immunol 1989; 19: 1463
   PubMed Web of Science ®Google Scholar
• Levy Y., Labaume S., Gendron M. C., Brouet J. C. Modulation of spontaneous B-cell differentiations in macroglobulinemia by retinoic acid. Blood 1994; 83: 206
   Google Scholar
• Ballester O. F., Moscinski L. C., Lyman G. H., Chaney J. V., Saba H. I., Spiers A. S. D., Klein C. High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood 1994; 83: 1903
   PubMed Web of Science ®Google Scholar
• Lokhorst H. M., Lamme T., de Smet M., Klein S., de Weger R. A., van Oers R., Bloem A. C. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994; 84: 2269
   PubMed Web of Science ®Google Scholar
• Uchiyama H., Barut B. A., Mohrbacher A. F., Chauhan D., Anderson K. C. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82: 3712
   PubMed Web of Science ®Google Scholar
• Hata H., Ziao H., Petrucci M. T., Woodliff J., Chang R., Epstein J. Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells. Blood 1993; 81: 3357
   PubMed Web of Science ®Google Scholar
• Tong A. W., Huang Y. W., Ghetie V., Nemunaitis J., Pineiro L., Vitetta E., Stone M. J. Enhancement of anti-CD54 immunotoxin cytotoxicity to human myeloma cells by cyclosporin drugs (abstract). Blood 1994; 84, (Suppl I)
   PubMed Web of Science ®Google Scholar
• Huang Y. M., Richardson J. A., Vitetta E. S. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Cancer Res 1995; 55: 610
   PubMed Web of Science ®Google Scholar